These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25672562)

  • 1. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
    Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
    Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Lee MH; Wen YW; Chang HK; Tseng CK; Liu YH
    Medicine (Baltimore); 2015 Feb; 94(8):e588. PubMed ID: 25715265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
    van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
    Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Wen YW; Chang HK; Tseng CK; Liu YH
    Eur J Surg Oncol; 2017 Dec; 43(12):2366-2373. PubMed ID: 29070435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy.
    Fujishima F; Taniyama Y; Nakamura Y; Okamoto H; Ozawa Y; Ito K; Ishida H; Konno-Kumagai T; Kasajima A; Taniuchi S; Watanabe M; Kamei T; Sasano H
    Dis Esophagus; 2018 Jul; 31(7):. PubMed ID: 29346536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of patients with esophageal squamous cell carcinoma who achieve major histopathological response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Eur J Surg Oncol; 2017 Jan; 43(1):234-239. PubMed ID: 27462024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic diagnosis and treatment of esophageal verrucous squamous cell cancer.
    Sweetser S; Jacobs NL; Wong Kee Song LM
    Dis Esophagus; 2014 Jul; 27(5):452-6. PubMed ID: 23067443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.
    Djuric-Stefanovic A; Micev M; Stojanovic-Rundic S; Pesko P; Saranovic Dj
    Eur J Radiol; 2015 Dec; 84(12):2477-84. PubMed ID: 26467704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa.
    Uchinami Y; Myojin M; Takahashi H; Harada K; Shimizu S; Hosokawa M
    Radiat Oncol; 2016 Jun; 11():84. PubMed ID: 27328734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.
    van Rossum PSN; Goense L; Meziani J; Reitsma JB; Siersema PD; Vleggaar FP; van Vulpen M; Meijer GJ; Ruurda JP; van Hillegersberg R
    Gastrointest Endosc; 2016 May; 83(5):866-79. PubMed ID: 26632523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.